Imipramine Hcl Cf

Imipramine, the active ingredient in Imipramine Hcl Cf, is a tricyclic antidepressant presented as an oral dosage form for oral use. It is employed in the management of major depressive disorder and nocturnal enuresis, primarily in adult patients. Imipramine works by modulating neurotransmitter levels in the brain, which helps improve mood and reduce involuntary urinary episodes.

GNH USA supplies Imipramine Hcl Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imipramine is a tricyclic antidepressant that influences monoamine neurotransmission and is indicated for specific mood and urinary disorders.

- Major depressive disorder: alleviates depressive symptoms such as low mood, loss of interest, and impaired concentration. - Enuresis (nocturnal urinary incontinence): reduces the frequency of nighttime bedwetting episodes in children and adolescents. - Maintenance therapy for recurrent depressive episodes: helps prevent relapse when used as part of a long‑term treatment plan.

Imipramine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dry mouth: reduced salivary flow leading to a persistent dry sensation. - Constipation: slowed gastrointestinal motility causing infrequent, hard stools. - Drowsiness: increased sedation, especially after initial dosing. - Blurred vision: temporary visual disturbances due to anticholinergic activity.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythms that may require monitoring. - Seizures: heightened risk in predisposed individuals. - Severe hypotension: sudden drop in blood pressure, particularly when standing. - Hepatotoxicity: liver enzyme elevations indicating possible liver injury. - Suicidal thoughts: emergence or worsening of suicidal ideation, especially early in therapy.

Before initiating therapy with Imipramine, clinicians should consider several safety measures. - Cardiac monitoring: obtain baseline ECG and monitor for arrhythmias, especially in patients with pre‑existing heart disease. - Suicidality assessment: evaluate for suicidal thoughts at treatment onset and during dose changes. - Gradual discontinuation: taper the dose to avoid withdrawal symptoms. - Elderly caution: start at lower doses and monitor for anticholinergic effects. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Imipramine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use may precipitate hypertensive crisis or serotonin syndrome. - Certain antiarrhythmic agents (e.g., quinidine): can increase the risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise imipramine plasma levels, requiring dose adjustment. - Anticholinergic drugs (e.g., diphenhydramine): additive anticholinergic burden may exacerbate dry mouth, constipation, and urinary retention. - CNS depressants (e.g., benzodiazepines, alcohol): can enhance sedation and impair psychomotor performance.